Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian)

重组抗EGFR人鼠嵌合单抗（三生国健）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian)
Drug Alias Name重组抗EGFR人鼠嵌合单克隆抗体（三生国健）CPGJ-602602CPGJ602CPGJ 602
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsAngiogenesis inhibitorsEpidermal growth factor inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1Epidermal growth factorP-glycoprotein 1 +[4] 
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A